BACKGROUND: The survival rates and prognostic factors for salivary duct carcinoma (SDC) are not clear. METHODS: Survival estimates and prognostic factors were evaluated for 228 patients with SDC identified from the Surveillance, Epidemiology, and End Results (SEER) database. RESULTS: Median overall survival (OS) duration for patients with SDC was 79 months and 5-year disease-specific survival (DSS) rate was 64%. Among patients with SDC with lymph node involvement, larger primary tumor size (>3 cm) was associated with twice the risk of death (p < .03). Factors predictive of improved DSS were age (p = .01), tumor size (p = .006), tumor grade (p = .02), and lymph node involvement (p < .001). Adjuvant radiotherapy did not improve survival when compared to surgery alone for early-stage (I-II) disease (p = .28). CONCLUSION: Younger patients with SDC (<50 years) showed a better prognosis. Primary tumor size and lymph node involvement were independent and additive risk factors for poor prognosis. The role of adjuvant radiotherapy in the treatment of SDC needs to be explored further.
BACKGROUND: The survival rates and prognostic factors for salivary duct carcinoma (SDC) are not clear. METHODS: Survival estimates and prognostic factors were evaluated for 228 patients with SDC identified from the Surveillance, Epidemiology, and End Results (SEER) database. RESULTS: Median overall survival (OS) duration for patients with SDC was 79 months and 5-year disease-specific survival (DSS) rate was 64%. Among patients with SDC with lymph node involvement, larger primary tumor size (>3 cm) was associated with twice the risk of death (p < .03). Factors predictive of improved DSS were age (p = .01), tumor size (p = .006), tumor grade (p = .02), and lymph node involvement (p < .001). Adjuvant radiotherapy did not improve survival when compared to surgery alone for early-stage (I-II) disease (p = .28). CONCLUSION: Younger patients with SDC (<50 years) showed a better prognosis. Primary tumor size and lymph node involvement were independent and additive risk factors for poor prognosis. The role of adjuvant radiotherapy in the treatment of SDC needs to be explored further.
Authors: Michael Jaehne; Kerstin Roeser; Thorsten Jaekel; Jan David Schepers; Natalie Albert; Thomas Löning Journal: Cancer Date: 2005-06-15 Impact factor: 6.860
Authors: E Martinez-Barba; J A Cortes-Guardiola; A Minguela-Puras; A Torroba-Caron; S Mendez-Trujillo; J Bermejo-Lopez Journal: J Craniomaxillofac Surg Date: 1997-12 Impact factor: 2.078
Authors: Martin G Dalin; Alexis Desrichard; Nora Katabi; Vladimir Makarov; Logan A Walsh; Ken-Wing Lee; Qingguo Wang; Joshua Armenia; Lyndsay West; Snjezana Dogan; Lu Wang; Deepa Ramaswami; Alan L Ho; Ian Ganly; David B Solit; Michael F Berger; Nikolaus D Schultz; Jorge S Reis-Filho; Timothy A Chan; Luc G T Morris Journal: Clin Cancer Res Date: 2016-04-21 Impact factor: 12.531
Authors: Peter P Luk; Christina I Selinger; Wendy A Cooper; Annabelle Mahar; Carsten E Palme; Sandra A O'Toole; Jonathan R Clark; Ruta Gupta Journal: Head Neck Pathol Date: 2018-11-22
Authors: Kyriakos Chatzopoulos; Andrea R Collins; Sotiris Sotiriou; Michael G Keeney; Daniel W Visscher; Michael Rivera; David J Schembri-Wismayer; Jean E Lewis; Patricia T Greipp; William R Sukov; Ashish V Chintakuntlawar; Katharine A Price; Joaquin J Garcia Journal: Head Neck Pathol Date: 2020-04-29
Authors: Ann-Jean C C Beck; Peter J F M Lohuis; Abrahim Al-Mamgani; Laura A Smit; Willem M C Klop Journal: Eur Arch Otorhinolaryngol Date: 2018-05-21 Impact factor: 2.503
Authors: Maximilian Linxweiler; Fengshen Kuo; Nora Katabi; Mark Lee; Zaineb Nadeem; Martin G Dalin; Vladimir Makarov; Diego Chowell; Snjezana Dogan; Ian Ganly; A Ari Hakimi; Richard J Wong; Nadeem Riaz; Alan L Ho; Timothy A Chan; Luc G T Morris Journal: Clin Cancer Res Date: 2020-02-14 Impact factor: 12.531